Skip to main content
. Author manuscript; available in PMC: 2020 Jan 5.
Published in final edited form as: Atherosclerosis. 2015 May 19;241(2):400–408. doi: 10.1016/j.atherosclerosis.2015.05.015

Table 2.

Metabolic profiles and fatty acid distributions in the three groups whose peripheral blood mononuclear cells (PBMC) underwent quantitative real-time polymerase chain reaction (Q-PCR) at both time points.

Olive Oil (n=16) EPA (n=16) DHA (n=18)
Plasma concentrations Baseline 6 weeks Baseline 6 weeks Baseline 6 weeks
Total cholesterol, mg/dL 206.8 ± 42.9 199.7 ± 40.4 189.8 ± 53.5 191.4 ± 43.9 205.2 ± 41.8 217.1± 37.5*
HDL cholesterol, mg/dL 59.3 ± 17.6 58.3 ± 16.8 58.1 ± 24.1 58.6 ± 24.5 53.2 ± 11.5 55.2 ± 13.3
LDL cholesterol, mg/dL 130.7 ± 44.1 124.4 ± 40.7 114.9 ± 35.1 115.6 ± 32.2 137.2 ± 39.6 144.0 ± 35.8
Triglyceride†, mg/dL 128.0 [76.5 - 174.0] 114.0 [92.8 - 168.5] 120.0 [76.0 - 181.0] 94.5 [76.0 - 183.5] 105.5 [75.3 - 123.5] 100.5 [74.5 - 143.5]
Glucose, mg/dL 87.7 ± 12.0 91.1 ± 17.9 93.4 ± 20.5 94.3 ± 14.2 88.2 ± 9.4 86.6 ± 7.0
Insulin†, μU/mL 9.9 [7.4 - 16.5] 10.0 [6.6 - 19.9] 7.9 [5.6 - 14.8] 8.0 [5.9 - 14.9] 8.0 [5.3 - 10.6] 7.8 [5.7 - 10.6]
Hs-CRP†, mg/dL 0.19 [0.07 - 0.35] 0.13 [0.06 - 0.24] 0.09 [0.06 - 0.16] 0.13 [0.06 - 0.25] 0.10 [0.05 - 0.40] 0.08 [0.04 - 0.28]
Lp-PLA2, ng/mL 194.0 ± 35.7 200.1 ± 40.8 196.9 ± 22.4 191.1 ± 30.8 238.1 ± 52.6# 212.6 ± 56.5**
Fatty acids Baseline 6 weeks Baseline 6 weeks Baseline 6 weeks
C18:1 n-9 (OA), % 9.8 ± 1.0 10.4 ± 1.7 9.9 ± 1.0 9.1 ± 1.1** 9.5 ± 1.2 9.4 ± 1.3
C20:4 n-6 (AA), % 13.2 ± 2.3 13.2 ± 2.5 12.8 ± 3.1 11.8 ± 2.9 11.7 ± 2.7 11.3 ± 2.6
C20:5 n-3 (EPA), % 0.78 ± 0.14 0.82 ± 0.10 0.91 ± 0.21 2.71 ± 0.45** 0.78 ± 0.16 1.11 ± 0.17*
C22:5 n-3 (DPA), % 0.83 ± 0.04 0.76 ± 0.04 0.86 ± 0.06 1.34 ± 0.11** 0.77 ± 0.05 0.62 ± 0.05**
C22:6 n-3 (DHA), % 2.8 ± 0.2 2.9 ± 0.2 3.0 ± 0.3 3.1 ± 0.4 3.0 ± 0.3 4.9 ± 0.7**

Data shown as mean ± standard deviation (or

†

mean [interquartile range]).

EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Hs-CRP, high-sensitivity C-reactive protein; Lp-PLA2, lipoprotein-associated phospholipase A2; OA, oleic acid; DPA, docosapentaenoic acid. Significant difference compared to baseline,

*

<0.05;

**

<0.01 within each group.

#

Significant difference in plasma Lp-PLA2 concentration between the DHA group and the other two groups.